Accessible Search Form           Advanced Search

HHS logo

Embargoed for Release: November 13, 2006

NHLBI Communications Office
nhlbi_news@nhlbi.nih.gov
301-496-4236
Ask for press officer on duty

Embargoed for Release: November 13, 2006

  • PRINT  |  SHARE

Media Availability: Greater Diabetes Risk in Patients Taking High Blood Pressure Medications

In a long-term study of older adults with high blood pressure from the National Heart, Lung, and Blood Institute of the National Institutes of Health, participants without diabetes who were taking high blood pressure medications experienced increased average fasting glucose levels. This was true regardless of which class of medication was used: diuretic, ACE inhibitor, or calcium channel blocker. During a 4 year period, the glucose changes led to new diagnoses of diabetes in approximately 1 in 10 participants (diuretic 11.0 percent, ACE inhibitor 7.8 percent and calcium channel blocker 9.3 percent .) However, the results of this Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) analysis showed no significant evidence that the new onset diabetes increased the risk of stroke, heart failure, or death from any cause, but it did increase the risk of heart attack. In those taking a diuretic, the relationship between new diabetes and coronary disease was actually less than in those taking the other drugs and not significant for the diuretic. According to the authors, this suggests that the glucose changes induced by diuretics do not lead to heart disease in the same way as diabetes caused by overweight, inactivity, and genetic predisposition. This finding is strongly supported by previous findings in a 14-year follow-up of the Systolic Hypertension in the Elderly Program (SHEP).

"Fasting Glucose and Incident Diabetes Mellitus in Older Non-diabetic Adults Randomized to Receive Three Different Classes of Antihypertensive Treatment," is published in the November 13, 2006 issue of Archives of Internal Medicine.

Jeffrey Cutler, M.D., co-author of the paper and project director of the ALLHAT study, is available to comment on the study's findings.

To schedule interviews, contact the NHLBI Communications Office at 301-496-4236.

Part of the National Institutes of Health, the National Heart, Lung, and Blood Institute (NHLBI) plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders. The Institute also administers national health education campaigns on women and heart disease, healthy weight for children, and other topics. NHLBI press releases and other materials are available online at: www.nhlbi.nih.gov.

The National Institutes of Health (NIH)—The Nation's Medical Research Agency—includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical, and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

For the Media

NHLBI Communications Office
nhlbi_news@nhlbi.nih.gov
301-496-4236
Ask for press officer on duty

Related Health Topics

High Blood Pressure